Noile-Immune BiotechTSE:4893 +4.07%53 Current Ratio is 53.54 as of Dec. 2025, which is 1% above its 10-year median of 53.02. GuruFocus rates TSE:4893 with a GF Score™ of 53/100 and a GF Value™ of 円4.36 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Noile-Immune Biotech ranks better than 99.22% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Noile-Immune Biotech's current ratio for the quarter that ended in Dec. 2025 was 53.54.
Noile-Immune Biotech has a current ratio of 53.54. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Noile-Immune Biotech's Current Ratio or its related term are showing as below:
TSE:4893'
s Current Ratio Range Over the Past 10 Years
Min: 13.68 Med: 53.02 Max: 68.77
Current: 62.52
During the past 6 years, Noile-Immune Biotech's highest Current Ratio was 68.77. The lowest was 13.68. And the median was 53.02.
TSE:4893's Current Ratio is ranked better than 99.22% of 1411
companies
in the Biotechnology industry
Industry Median: 3.91
vs TSE:4893: 62.52
Noile-Immune Biotech (TSE:4893) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Noile-Immune Biotech Current Ratio Related Terms
Noile-Immune Biotech Current Ratio Historical Data
* Premium members only.
The historical data trend for Noile-Immune Biotech's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4893 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Noile-Immune Biotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noile-Immune Biotech Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Current Ratio distribution charts can be found below:
* The bar in red indicates where Noile-Immune Biotech's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noile-Immune Biotech (TSE:4893) has a Current Ratio of 53.54 as of Dec. 2025. This is near median its historical median of 53.02. Over the past decade, Noile-Immune Biotech's Current Ratio has ranged from 13.68 to 68.77. According to the industry distribution chart, Noile-Immune Biotech ranks #11 out of 1411 companies in the Biotechnology industry, placing it in the top 0.8%.
Is Noile-Immune Biotech's Current Ratio too high?
Noile-Immune Biotech's current Current Ratio of 53.54 is near median its 10-year median of 53.02. Over the past 10 years, this metric has ranged from a low of 13.68 to a high of 68.77. The Biotechnology industry median Current Ratio is 3.91. Noile-Immune Biotech's value of 53.54 is 1269.3% above this industry median. Based on the distribution chart, Noile-Immune Biotech ranks #11 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Noile-Immune Biotech has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Noile-Immune Biotech ranks #11 out of 1411 companies for Current Ratio. This places Noile-Immune Biotech in the top 1% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.91. Noile-Immune Biotech's value of 53.54 is 1269.3% above this benchmark. Historically, Noile-Immune Biotech's own Current Ratio has ranged from 13.68 to 68.77 over the past decade. While the company's 10-year median is 53.02 vs. the industry median of 3.91, Noile-Immune Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.91, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Noile-Immune Biotech's current Current Ratio of 53.54 is 1269.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noile-Immune Biotech's current Current Ratio is 53.54, which is near median its own 10-year median of 53.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.36, compared to a current price of 円128.00 — trading 2835.8% above its estimated fair value. The current Current Ratio is 53.54, which is near median its 10-year median of 53.02 and 1269.3% above the Biotechnology industry median of 3.91. Noile-Immune Biotech's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Current Ratio is 53.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?
Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued.
The current stock price of 円128.00 is trading 2835.8% above its estimated GF Value™ of 円4.36.
GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.
Key valuation signals for TSE:4893:
Current Ratio: 53.54 (near median its 10-year median of 53.02)
GF Value™: 円4.36 vs. price of 円128.00 (2835.8% above fair value)
Industry Position: 1269.3% above the Biotechnology median (#11 of 1411)
No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
53GF Score
Get the complete analysis for TSE:4893
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4893 has been successfully added to your 
